Physician profile
Manish Raval
NPI 1609961952
$1,006.05
in general payments reported to CMS, 2019-2025
20 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $327 · 2021: $207 · 2022: $72.66 · 2023: $21.88 · 2024: $20.11 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $194.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $225.87 | 2019-2022 | |
| Novo Nordisk INC | $189.84 | 2020-2024 | Rybelsus |
| Amarin Pharma, INC. | $71.44 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $67.30 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $63.28 | 2020-2025 | Shingrix, Bexsero, Arexvy |
| Braeburn INC. | $62.10 | 2025 | Brixadi |
| Global Blood Therapeutics, INC. | $54.39 | 2020 | |
| Indivior INC. | $47.63 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $28.41 | 2020 | |
| Orexo US, INC. | $22.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.28 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.40 | 2019 | |
| Genentech USA, INC. | $18.04 | 2020 | |
| Seqirus USA INC | $17.86 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $17.75 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.19 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.24 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $14.07 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $13.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Raval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.